BidaskClub upgraded shares of AC Immune (NASDAQ:ACIU) from a strong sell rating to a sell rating in a research report released on Friday.
Several other analysts have also recently commented on the company. Zacks Investment Research cut AC Immune from a buy rating to a hold rating in a report on Tuesday. ValuEngine cut AC Immune from a buy rating to a hold rating in a report on Monday, August 20th. Finally, HC Wainwright set a $18.00 price target on AC Immune and gave the company a buy rating in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $14.00.
AC Immune stock traded up $0.63 during mid-day trading on Friday, reaching $8.64. 169,630 shares of the company were exchanged, compared to its average volume of 119,453. AC Immune has a twelve month low of $7.16 and a twelve month high of $17.40. The company has a current ratio of 9.65, a quick ratio of 9.65 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $526.90 million, a price-to-earnings ratio of -28.80 and a beta of 2.22.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Article: Stop Order
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.